GNA15 and acute myeloid leukemia: Moreover, in the NK-AML without FLT3-ITD mutations, subjects with high GNA15 expression showed a worse 2-year OS (13.7% [0%-50.7%] vs 44.5% [18.2%-70.8%], P=0.0115; Figure 2E) and a similar 2-year RFS (32.3% [0%-65.0%] vs 40.6% [13.6%-67.6%], P=0.1715; Figure 2F).